What is Antibody Drug Conjugate Market?
Over the years, a number of companies(small or well-funded start-ups), offering novel conjugation technologies, more potent warheads, and advanced linker technologies, have been established. Moreover, the multiple collaborations licensing agreements, have been inked in the past few years between technology providers and drug developers to advance the development of pipeline Antibody Drug Conjugate candidates. Antibody-Drug Conjugates is a matter made up of a monoclonal antibody chemically linked to a drug. The monoclonal antibody binds to specific proteins on certain types of cells, such as cancer cells. These drug enters these cells and kills them without harming other cells. Some antibody-drug conjugates are used to treat cancer. Also called ADC. According to the research done by the World Health Organization, in 2018 some 18 million people around the world were diagnosed with cancer and some 9.6 million died of the disease. Cancers of the digestive organs, lungs are more common, affecting both men and women, while breast and cervical cancer are naturally prevalent among women. The growing popularity and therapeutic possiblity of Antibody Drug Conjugate can also be correlated with an exponential rise in the number of patents that have been granted
The market study is being classified, by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer and Brain Tumor) and major geographies with country level break-up.
Pfizer (United States), Progenics Pharmaceuticals(United States), Novartis (Switzerland), Eli Lilly(United States), Genentech(United States), Genmab (Denmark), Amgen (United States), Bayer HealthCare (Germany), Celldex Therapeutics(United States) and Concortis Biotherapeutics(United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Mersana Therapeutics(United States), Millennium Pharmaceuticals(United States), AbbVie (United States) and Agensys(United States).
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Antibody Drug Conjugate market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Antibody Drug Conjugate market by Type, Application and Region.
On the basis of geography, the market of Antibody Drug Conjugate has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- The Growing Geriatric Population Is Expected To Drive Growth Of The Market Over The Forecast Period.
- Increasing Incidence Of Cancer Coupled With Growing Geriatric Population
- Emergence Of Cancer Treatment Options
- The adverse effect of the treatment
- Innovative Drug Development Opening A New Horizon In Cancer Therapy
- High cost of the treatment
Market Leaders and some development strategies
In September 2020 Gileadís the United States Based Phamacitiucals Company Has USD 21 Billion Purchase Of Immunomedics Boosts ADC Field.
Key Target AudienceAntibody-Drug Conjugate Providers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase